Indications And Dose
Reduction in the duration of neutropenia and associated complications following bone-marrow transplantation for non-myeloid malignancy (specialist use only) | Reduction in the duration of neutropenia and associated complications following peripheral stem cells transplantation for non-myeloid malignancy (specialist use only) ▶BY INTRAVENOUS INFUSION, OR BY SUBCUTANEOUS INJECTION ▶Adult: 150 micrograms/m2 daily until neutrophil count stable in acceptable range (max. 28 days), to be started the day after transplantation. Intravenous infusion to be given over 30 minutes Reduction in the duration of neutropenia and associated complications following treatment with cytotoxic chemotherapy associated with a significant incidence of febrile neutropenia (specialist use only) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 150 micrograms/m2 daily until neutrophil count stable in acceptable range (max. 28 days), to be started on the day after completion of chemotherapy Mobilisation of peripheral blood progenitor cells for harvesting and subsequent infusion, used alone (specialist use only) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 10 micrograms/kg daily for 4–6 days (5–6 days in healthy donors) Mobilisation of peripheral blood progenitor cells, used following adjunctive myelosuppressive chemotherapy (to improve yield) (specialist use only) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 150 micrograms/m2 daily until neutrophil count stable in acceptable range, to be started 1–5 days after completion of chemotherapy, for timing of leucopheresis, consult product literature
PDF page 1112